Access BayerPRO

<p>Stay up to date with exclusive content for Healthcare Professionals:</p><ul><li>Latest updates</li><li>Find useful tools for your practice</li><li>Access patient support materials</li></ul>

Sign up to BayerMED:

Register | Login For Further Access

404 Page

Default

You Are About To Leave The Current Site

Training

Training Title

Learning Materials

Medical Literature 

Chronic Kidney Disease 

Awareness​

Menopause

Clinical Tools 

Contraception

Women's Health

Medical Literature

Prostate Cancer

Heart Failure 

Oncology

Cardio Renal 

Ophthalmology

Bayer Logo

Womens Health.png

Plain Blue Hero Banner.png

Other

small_Cardiovascular_32px.png

Heart Failure

small_Ophthalmology_32px.png

Oncologie

Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study

media:remote_media:a85e890a-5087-4434-b1b3-85266930c9d1

Safety and Survival of 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer Post-223Ra: The RALU Study

Ask a Question